The merger combining Vision-Sciences and Uroplasty into Cogentix Medical was completed Wednesday. Uroplasty CEO Rob Kill will be in control of the new company, which will have its headquarters in Minnetonka, Minn., and will concentrate on the treatment and diagnosis of urologic disorders.
Uroplasty and Vision-Sciences have agreed to merge in the first half of 2015. The new company, which will be called Cogentix Medical, will be based in Minnetonka, Minn., and focus on medical devices for urologic treatment and diagnosis. Rob Kill, president and CEO of Uroplasty, will continue his role in Cogentix.
InVivo Therapeutics, maker of a biopolymer scaffold designed to treat acute spinal cord injury, has tapped Steven McAllister to serve as its chief financial officer on an interim basis. McAllister has worked with various medtech companies, most recently as vice president of finance and administration at Biomet.
Brett Reynolds has been appointed to succeed Mahedi Jiwani as chief financial officer at Uroplasty. Reynolds previously served as CFO for Synovis Life Technologies for nine years before he went on to lead the Minnesota site of Baxter Healthcare, which acquired Synovis for $325 million last year.
Richard Brajer has resigned as CEO of LipoScience after working with the diagnostics company for 10 years. Robert Greczyn, who is a member of the company's board, has taken over as CEO on an interim basis.